PHOTO
Aug 24 (Reuters) - Drugmaker Hikma Pharmaceuticals Plc
HIK.L
said its core operating profit fell 14 percent to $176 million, hurt by lower contribution from specific market opportunities for its generics business.
** The Jordanian company, which makes and markets branded and non-branded generic and injectable drugs, reported revenue of $882 million for six months ended June 30.
** Hikma warned in August that full-year core operating profit from its generics unit would be hurt by delayed approvals of new products and higher-than-expected costs.
** Generics segment accounted for 30 percent of company's first-half revenue.
** Hikma bought Boehringer's U.S. generic drug business for $2.65 bln in 2015, as it tried to gain scale in a highly competitive part of the pharmaceutical market.
** It said on Wednesday that it is making significant progress with integration and is on track to deliver cost synergies for the Boehringer deal.
** Hikma said it continued to expect 2016 revenue to be in the range of $2.0 billion to $2.1 billion.
(Reporting by Rahul B in Bengaluru; Editing by Sunil Nair) ((Rahul.B@thomsonreuters.com; UK: +44 20 7542 1810; Outside UK: +91 80 6749 1136; Reuters Messaging: rahul.b.thomsonreuters.com@reuters.net))
** The Jordanian company, which makes and markets branded and non-branded generic and injectable drugs, reported revenue of $882 million for six months ended June 30.
** Hikma warned in August that full-year core operating profit from its generics unit would be hurt by delayed approvals of new products and higher-than-expected costs.
** Generics segment accounted for 30 percent of company's first-half revenue.
** Hikma bought Boehringer's U.S. generic drug business for $2.65 bln in 2015, as it tried to gain scale in a highly competitive part of the pharmaceutical market.
** It said on Wednesday that it is making significant progress with integration and is on track to deliver cost synergies for the Boehringer deal.
** Hikma said it continued to expect 2016 revenue to be in the range of $2.0 billion to $2.1 billion.
(Reporting by Rahul B in Bengaluru; Editing by Sunil Nair) ((Rahul.B@thomsonreuters.com; UK: +44 20 7542 1810; Outside UK: +91 80 6749 1136; Reuters Messaging: rahul.b.thomsonreuters.com@reuters.net))
